Evidence map›Paper›PMID 36743295›Full record

ArticleRevista espanola de cardiologia2023

[Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management].

Manuel Barreiro-Pérez, Pablo Pastor Pueyo, Sergio Raposeiras-Roubín, Dolores Montero Corominas, Aitor Uribarri, Rocío Eiros Bachiller, José Rozado Castaño, Luisa García-Cuenllas Álvarez, Luis Serratosa Fernández, Fernando Domínguez and 1 more

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Revista espanola de cardiologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 1 country.

Manuel Barreiro-PérezServicio de Cardiología, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, España.
Pablo Pastor PueyoUnidad de Cardiología Clínica y Cuidados Agudos Cardiovasculares, Hospital Universitario Arnau de Vilanova, Lleida, España.
Sergio Raposeiras-RoubínServicio de Cardiología, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, España.
Dolores Montero CorominasDivisión de Farmacoepidemiología y Farmacovigilancia, Departamento de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, España.
Aitor UribarriServicio de Cardiología, Hospital Universitario Vall d'Hebron, Barcelona, España.
Rocío Eiros BachillerServicio de Cardiología, Hospital Clínico Universitario de Salamanca, Salamanca, España.
José Rozado CastañoServicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España.
Luisa García-Cuenllas ÁlvarezCardiología Pediátrica, Servicio de Pediatría, Hospital Vithas Vigo, Vigo, Pontevedra, España.
Luis Serratosa FernándezUnidad de Cardiología del Deporte, Hospital Universitario Quirónsalud Madrid, Madrid, España.
Fernando DomínguezServicio de Cardiología, Hospital Universitario Puerta de Hierro, Madrid, España.
Domingo Pascual FigalServicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, España.
University Hospital Complex Of Vigo · ESAgencia Española de Medicamentos y Productos Sanitarios · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESComplejo Hospitalario de Salamanca · ESHospital Universitari Arnau de Vilanova · ESHospital Universitario Central de Asturias · ESHospital Universitario Quirónsalud Madrid · ESSpanish National Centre for Cardiovascular Research · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has revealed several cardiovascular complications, including myocarditis caused by SARS-CoV-2 infection (COVID-19) or after messenger RNA vaccine administration. Because of the high prevalence of COVID-19, the expansion of vaccination programs, and the appearance of new information on myocarditis in these contexts, there is a need to condense the knowledge acquired since the start of the pandemic. To meet this need, this document was drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology, with the collaboration of the Spanish Agency for Medicines and Health Products (AEMPS). The document aims to address the diagnosis and treatment of cases of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration.

Indexed as

COVID-19mRNA vaccineMyocardial damageMyocarditisSARS-CoV-2

Identifiers

PMID36743295
PMCPMC9884510
OpenAlexW4318447337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.